Intensity Therapeutics, Inc. (Nasdaq: INTS), a biotechnology company specializing in the development of immune-based intratumoral cancer therapies, announced that its product INT230-6 achieved a 100% complete response rate in preclinical models of Malignant Peripheral Nerve Sheath Tumors (MPNST). The study was conducted in collaboration with the Staedtke-Bai laboratory at Johns Hopkins University. Over a period of 21 days, all animals treated with INT230-6 in the study achieved complete responses, while tumors in the control group continued to grow. These results have been presented and mark the first instance of INT230-6 being used on a neurological-specific tumor, with plans for further preclinical research on other neurological cancer models.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。